Skip to main content

Table 3 Univariate and multivariate analysis using a cumulative logistic regression method to predict histologic upgrade to microinvasion and invasion

From: The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ

 

Univariate analysis

 

Multivariate analysis

 
 

Odds ratio (95% CI)

P value

Adjusted Odds ratio (95% CI)

P value

Age (old vs. young)

1.02 (1.00–1.05)

0.070

  

Biopsy method (US-CNB vs. SVAB)

2.78 (1.28–6.01)

0.009

  

Nuclear grade (grade 3 vs. grade 1–2)

7.51 (2.38–23.75)

< 0.001

  

Necrosis (present vs. absent)

1.74 (1.02–2.98)

0.044

  

ER (absent vs. present)

2.97 (1.63–5.38)

< 0.001

  

PR (absent vs. present)

3.53 (2.02–6.17)

< 0.001

2.40 (1.29–4.44)

0.006

HER2 (present vs. absent)

2.81 (1.62–4.87)

< 0.001

  

Ki-67 (high vs. low)

3.44 (1.98–6.00)

< 0.001

2.42 (1.30–4.50)

0.005

Mammographic calcification (present vs. absent)

1.70 (0.96–3.02)

0.072

  

BPE on MRI (minimal or mild vs. moderate or marked)

1.88 (1.00–3.55)

0.051

  

MR type of lesion (mass or NME vs. non-visualization)

  Mass

8.81 (1.10–70.93)

0.041

8.84 (1.05–74.04)

0.045

NME

11.95 (1.50–95.20)

0.019

11.17 (1.35–92.36)

0.025

  1. CI confidence interval; US-CNB US-guided core needle biopsy; SVAB stereotactic vacuum-assisted biopsy; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2; BPE background parenchymal enhancement; NME non-mass enhancement